Management of Non-Alcoholic Fatty Liver Disease in Primary Care

Non-alcoholic fatty liver disease (NAFLD) affects roughly a quarter of adults worldwide and is closely linked to obesity, type 2 diabetes and other cardiometabolic risk factors. Primary care practitioners are uniquely positioned to detect early liver steatosis, stratify fibrosis risk and implement lifestyle and pharmacological interventions before progression to cirrhosis or non-alcoholic steatohepatitis (NASH). Core elements of management include routine assessment of liver enzyme abnormalities, use of validated non-invasive fibrosis tests, targeted referral pathways to specialist care and structured advice on diet, exercise and weight loss. Integration of cardiometabolic risk assessment into NAFLD protocols is essential given the high burden of cardiovascular morbidity. Emerging care models emphasise multidisciplinary collaboration, digital decision support and patient education to ensure timely case finding, risk stratification and long-term surveillance in the community setting.

Research from Nature Portfolio

Recent studies have outlined a collaborative framework for advancing NAFLD management at the community level. A key report described outcomes from a multi-stakeholder workshop in which primary care physicians, hepatologists, policy makers and patient advocates mapped out care pathways, identified knowledge gaps and proposed strategies for optimising resource use. Innovations include integration of electronic decision-support tools to guide non-invasive fibrosis testing, streamlined criteria for referral to secondary care and pilot programmes for remote monitoring of lifestyle interventions. The consensus emphasises the need for training modules for primary care teams, consensus on fibrosis thresholds and stronger alignment of primary care guidelines with emerging therapies under clinical development.

Management of Non-Alcoholic Fatty Liver Disease in Primary Care publication trend

The graph below shows the total number of articles in management of non-alcoholic fatty liver disease in primary care across all publications each year (not limited to Nature Index journals).

Technical terms

Fibrosis-4 (FIB-4) score: A simple index derived from age, liver enzymes and platelet count used to estimate liver fibrosis risk.

Enhanced Liver Fibrosis (ELF) test: A blood biomarker panel measuring markers of extracellular matrix turnover to assess liver fibrosis severity.

Transient elastography: An ultrasound-based technique that quantifies liver stiffness as a surrogate for fibrosis stage.

Non-alcoholic steatohepatitis (NASH): An inflammatory subtype of NAFLD characterised by hepatocyte injury and higher risk of progression to cirrhosis.

Cardiometabolic risk factors: Conditions such as obesity, type 2 diabetes, hypertension and dyslipidaemia that increase cardiovascular and liver disease progression.

References

1. National study of NAFLD management identifies variation in delivery of care in the UK between 2019 to 2022. JHEP Reports (2023).
2. A multistakeholder approach to innovations in NAFLD care. Communications Medicine (2023).
3. Prospective evaluation of a primary care referral pathway for patients with non-alcoholic fatty liver disease. Journal of Hepatology (2019).
4. Cost-comparison analysis of FIB-4, ELF and fibroscan in community pathways for non-alcoholic fatty liver disease. BMC Gastroenterology (2019).